Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people reach week 2 of tirzepatide still on the 2.5 mg starter dose, and the most honest answer to what happens is this: not much on the scales yet, and that is entirely normal. The first fortnight is about your body adjusting to the medicine, not about measurable weight loss. Tirzepatide is a prescription-only medicine that requires clinical assessment before a prescriber can approve it for you; any physical changes this early reflect how your system is responding, not how much fat has been lost.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A common misconception is that if you have not noticed the scales shifting by day ten or twelve, something has gone wrong. It hasn't. The 2.5 mg dose that almost everyone starts on is a tolerability dose: its job is to introduce your system to a dual GIP and GLP-1 receptor agonist gradually, reducing the chance of significant nausea or gut upset, not to deliver immediate therapeutic effect. You can read more about what week one typically feels like to see how little usually changes in those first seven days, and a closer look at tirzepatide week 1 gives further detail on what that opening period involves.
Tirzepatide works partly by slowing how quickly food moves through the stomach, which affects how soon you feel full and how long that fullness lasts. At 2.5 mg, this effect is present but gentle. The clinical trials that produced the headline results ran for 72 weeks, not two. Understanding that timeline makes week 2 feel less anticlimactic and a great deal more manageable.
If you are curious about how the progression looks beyond this point, the full timeline for tirzepatide's effects covers what most people notice at each stage.
The side-effect profile at this stage is dominated by the digestive system. Nausea is the most frequently reported experience, followed by loose stools, constipation, mild reflux and burping. For many people these symptoms peak in the first week or two then gradually settle; for others they barely appear at all. Neither pattern means the medicine is or is not working.
According to the NHS medicines page for tirzepatide, these gastrointestinal effects are well-recognised and typically mild to moderate in intensity. Eating smaller portions, avoiding very fatty or spicy meals, and staying well-hydrated all help. Your Patient Information Leaflet has specific guidance on managing them; your prescriber is also there to help if anything concerns you.
One thing worth knowing: injection-site reactions (mild redness, itching or a small lump where you inject) are also possible in early weeks. Rotating between the abdomen, thigh and upper arm keeps any one site from becoming irritated. If you have questions about your experience so far, our clinical support team is available seven days a week.
Some people describe a noticeable drop in appetite by the end of the first week; others reach week 2 feeling much as they did before starting. Both are within the normal range. Appetite suppression tends to become more consistent and reliable as the dose increases over subsequent months, so week 2 is not a reliable guide to how you will respond at higher doses.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, involved around 2,500 adults and found average weight reductions of roughly 20–21% at the 15 mg dose over 72 weeks. Those results did not arrive in a fortnight. They built up gradually as participants moved through the titration schedule under clinical supervision, which is exactly why patience in the early weeks matters.
For a fuller picture of how results accumulate week by week, the four-week results page covers what most people notice once the first month is complete.
Practically speaking, week 2 looks the same as week 1: one 2.5 mg injection on your chosen weekly day, stored in the fridge between uses, taken at a consistent time. Your prescriber sets the schedule; the Patient Information Leaflet covers the exact injection technique and storage details. Do not change your dose or timing without speaking to your prescriber first.
Small dietary adjustments are worth making if nausea is an issue: lighter meals, slower eating and cutting back on alcohol tend to help. Keeping up gentle activity is reasonable if you feel well enough; heavy exercise when nausea is present is not necessary and not expected at this stage. There is useful background on what weight loss on tirzepatide looks like over time if you want to situate week 2 within the longer arc of treatment.
If you are not yet on treatment and are wondering whether tirzepatide might be right for you, checking your eligibility with our prescribers is the right starting point. Every consultation at nume is reviewed the same day by a real GPhC-registered prescriber, not an automated system.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.